The Majority of Surveyed Gastroenterologists and MCOs Select Centocor Ortho Biotech/Merck/Mitsubishi Tanabe Pharma's Remicade as the Most Efficacious Currently Available Therapy for the Treatment of Moderate to Severe Ulcerative Colitis Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, when compared to other currently available agents, Centocor Ortho Biotech/Merck/Mitsubishi Tanabe Pharma's Remicade (infliximab) was selected as the most efficacious therapy for the treatment of moderate to severe ulcerative colitis by the majority (57 percent) of surveyed gastroenterologists. Remicade was also selected as the most efficacious therapy for the disease by the highest percentage (70 percent) of surveyed managed care organization's (MCOs) pharmacy directors. The findings from Decision Resources' analysis of the ulcerative colitis drug market reveal that, when considering all assessed efficacy end points, surveyed gastroenterologists who regard Remicade as the most efficacious therapy were most satisfied with the drug's ability to induce a response, its effect on surgical intervention and its effect on mucosal healing. However, surveyed physicians were least satisfied with Remicade's effect on maintenance of response. This finding is likely owing to Remicade's waning efficacy in the maintenance setting, as interviewed thought leaders report that patients often lose response to Remicade over time. Surveyed MCOs that chose Remicade as the most efficacious therapy were most satisfied with its effect on inducing remission, which is consistent with surveyed physicians' opinions. However, surveyed gastroenterologists and MCOs do not agree on which drug is the safest and most tolerable among available